NRX Pharmaceuticals, Inc. Quarterly Nonoperating Income (Expense) in USD from Q4 2017 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
NRX Pharmaceuticals, Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from Q4 2017 to Q3 2024.
  • NRX Pharmaceuticals, Inc. Nonoperating Income (Expense) for the quarter ending September 30, 2024 was $1.4M.
  • NRX Pharmaceuticals, Inc. Nonoperating Income (Expense) for the twelve months ending September 30, 2024 was $96K.
  • NRX Pharmaceuticals, Inc. annual Nonoperating Income (Expense) for 2023 was -$2.31M, a 150% decline from 2022.
  • NRX Pharmaceuticals, Inc. annual Nonoperating Income (Expense) for 2022 was $4.58M, a 79.8% decline from 2021.
  • NRX Pharmaceuticals, Inc. annual Nonoperating Income (Expense) for 2021 was $22.7M.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $96K $1.4M +$1.65M Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-14
Q2 2024 -$1.56M -$847K -$318K -60.1% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-14
Q1 2024 -$1.24M -$530K +$1.07M +67% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-14
Q4 2023 -$2.31M $74K +$426K Oct 1, 2023 Dec 31, 2023 10-K 2024-03-29
Q3 2023 -$2.74M -$254K -$312K -538% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-14
Q2 2023 -$2.43M -$529K -$3.15M -120% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 $720K -$1.6M -$3.86M -171% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
Q4 2022 $4.58M -$352K -$22.9M -102% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-29
Q3 2022 $27.5M $58K +$17M Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 $10.5M $2.62M -$14.4M -84.6% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 $24.9M $2.26M +$2.14M +1846% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 $22.7M $22.6M +$23.4M Oct 1, 2021 Dec 31, 2021 10-K 2023-03-31
Q3 2021 -$675K -$17M -$16.9M -135359% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 $16.3M $17M +$17M Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-15
Q1 2021 -$739K $116K -$349K -75.1% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-16
Q4 2020 -$390K -$840K -$1.01M -588% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-31
Q3 2020 $622K -$12.5K -$271K -105% Jul 1, 2020 Sep 30, 2020 10-Q/A 2022-08-12
Q2 2020 $893K -$2.53K -$395K -101% Apr 1, 2020 Jun 30, 2020 10-Q/A 2022-08-12
Q1 2020 $1.29M $465K +$82.3K +21.5% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-21
Q4 2019 $1.21M $172K -$147K -46.1% Oct 1, 2019 Dec 31, 2019 10-K/A 2021-05-14
Q3 2019 $1.35M $258K -$25.1K -8.85% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-16
Q2 2019 $1.38M $392K +$118K +43.1% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-14
Q1 2019 $1.26M $383K +$171K +80.6% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-15
Q4 2018 $1.09M $319K +$290K +985% Oct 1, 2018 Dec 31, 2018 10-K 2019-03-15
Q3 2018 $799K $283K Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-14
Q2 2018 $274K Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-14
Q1 2018 $212K Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-15
Q4 2017 $29.4K Sep 18, 2017 Dec 31, 2017 10-K 2019-03-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.